Application of Regulating Intestinal Flora in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000029849

Enrollment

Unknown

Registered

2020-02-15

Start date

2020-02-01

Completion date

Unknown

Last updated

2020-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Experimental group:Regulating intestinal flora + conventional treatment

Control group:conventional treatment

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Participants with 18 to 75 years of age who have been diagnosed with NCP by nucleic acid testing and meet the clinical classification of severe NCP referring to the clinical classification standard in the General Office of the National Health and Health Commission-Novel Coronavirus Pneumonia Diagnosis and Treatment Program (Trial Version 4).

Exclusion criteria

Exclusion criteria: Participants who have used fluoroquinolone antibiotics within 1 week

Design outcomes

Primary

Measure	Time frame
Length of admission;mortality rate;	—

Secondary

Measure	Time frame
Tempreture;PSI score;	—

Countries

China

Contacts

Public ContactHuaqi Wang

The First Affiliated Hospital of Zhengzhou University

wanghuaqi2004@126.com+86 15890689220

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026